Home | Orsiro

Test the next level of deliverability with Orsiro Mission

call out

Outstanding patient outcomes3​​​​​​​

∆ Posterior probability of superiority in STEMI in c​​​​​​​omparison to Xience at 24-months in the BIOSTEMI trial, with respect to TLF, based on combined data set of BIOSTEMI and BIOSCIENCE STEMI groups.

​​​​​​​*Based on TLF rates. 

1. In comparison to Xience Sierra, Resolute Onyx and Synergy for bench tests on pushability, trackability and crossability, BIOTRONIK data on file; 2. As characterized with respect to strut thickness in Bangalore et al. Meta-analysis; 3. Based on investigator’s interpretation of BIOFLOW-V primary endpoint results; 4. BIOTRONIK data on file, status January 2020. 5. Pilgrim et al. Biodegradable – versus durable-polymer drug-eluting stents for STEMI. Final 2-year outcomes of the BIOSTEMI trial. J Am Coll Cardiol. Cardiovasc Interven. 2021, doi: 10.1016/j.jcin.2020.12.011.

Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies.

Clinical data conducted with Orsiro, Orsiro Mission’s predecessor device can be used to illustrate Orsiro Mission clinical outcomes. 

Orsiro Mission is currently not available in the US.

© 2021 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.